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Abstract
Selenium supplement has been shown in clinical trials to reduce the risk of different cancers 
including lung carcinoma. Previous studies reported that the antiproliferative and pro-apoptotic 
activities of methylseleninic acid (MSA) in cancer cells could be mediated by inhibition of the 
PI3K pathway. A better understanding of the downstream cellular targets of MSA will provide 
information on its mechanism of action and will help to optimise its use in combination therapies 
with PI3K inhibitors. For this study, the effects of MSA on viability, cell cycle, metabolism, 
apoptosis, protein and mRNA expression, and Reactive Oxygen Species production were analysed 
in A549 cells. FOXO3a subcellular localisation was examined in A549 cells and in stably 
transfected human osteosarcoma U2foxRELOC cells. Our results demonstrate that MSA induces 
FOXO3a nuclear translocation in A549 cells and in U2OS cells that stably express GFP-FOXO3a. 
Interestingly, sodium selenite, another selenium compound, did not induce any significant effects 
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on FOXO3a translocation despite inducing apoptosis. Single strand break of DNA, disruption of 
tumour cell metabolic adaptations, decrease in ROS production, and cell cycle arrest in G1 
accompanied by induction of apoptosis are late events occurring after 24 h of MSA treatment in 
A549 cells. Our findings suggest that FOXO3a is a relevant mediator of the antiproliferative 
effects of MSA. This new evidence on the mechanistic action of MSA can open new avenues in 
exploiting its antitumour properties and in the optimal design of novel combination therapies. We 
present MSA as a promising chemotherapeutic agent with synergistic antiproliferative effects with 
cisplatin.
Keywords
Methylseleninic acid; Selenium; FOXO; Akt; PI3K; Cisplatin
1. Introduction
Lung cancer is a leading cause of cancer-related mortality and has one of the lowest cure 
rate worldwide [1]. In early stages of the disease, surgery is the common choice while 
chemotherapy is the main treatment in advanced lung cancer. The search for new synthetic 
or natural drugs with low systemic toxicity and high efficiency holds great promise to 
decrease the morbidity and mortality of cancer. The trace element selenium (Se) in various 
chemical forms is nutritionally essential for humans but has toxic activity at higher levels [2, 
3]. To date, the antioxidant and chemopreventive role of different Se agents as a dietary 
supplement has not been completely elucidated [4]. Se compounds such as sodium selenite 
(Na2SeO3) [5, 6] and methylseleninic acid (CH3SeO2H, abbreviated as MSA) have also 
been studied as potential anticancer agents. MSA is a synthetic precursor of methylselenol 
(CH3SeH) which induces several cellular, transcriptional and biochemical responses that 
differ from those induced by selenium forms that are transformed via hydrogen selenide, 
such as sodium selenite [7, 8].
As a constituent of the selenocysteine-containing selenoproteins, selenium has a key role in 
redox regulation and defence against oxidative stress by greatly enhancing the activity of 
some antioxidant enzyme systems [9]. Several selenoenzymes, including thioredoxin 
reductase, iodothyronine deiodinase and glutathione peroxidase, may be associated with 
cancer development and progression by modulating cell proliferation, transformation, 
migration and protection against oxidative damage [2]. Selenium deficiency has also been 
linked to cancer development since it was observed that populations with low selenium 
intake had greater cancer incidence. Numerous studies and clinical trials have shown that 
supranutritional doses of individual and mixed selenium compounds inhibit proliferation of 
cancer cells, induce tumour cell apoptosis, suppress tumour formation and metastasis in 
animal models and reduce the risk of prostate, lung, breast, and colorectal cancers in humans 
[9–11]. However, not all selenium compounds have efficacy in chemoprevention, as in a 
recent large clinical trial (SELECT), selenomethionine was concluded to be ineffective in 
reducing the risk for prostate cancer development [12].
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Using a stable isotope-resolved metabolomic (SIRM) approach, Fan and collaborators [13] 
reported that several metabolites, including lactate, glutathione and glutamate are depleted in 
A549 lung cancer cells by selenite but not by selenomethionine, suggesting multiple 
perturbations of the central metabolic networks. Interestingly, the reduction in glycolysis, 
tricarboxylic acid cycle (TCA) and pentose phosphate pathway (PPP) fluxes observed is 
opposite to those observed when phosphoinositide-3-kinase (PI3K) pathway is activated 
[14], pointing to the hypothesis that Se agents target this signalling pathway. Among the 
selenium compounds with anticancer properties, it has been reported that MSA is a potent 
inhibitor of the growth and survival of human umbilical vein endothelial cells (HUVECs) 
and that this antiproliferative effect could be enacted through the PI3K pathway [15, 16]. 
Studies with prostate cancer LNCaP, PC-3 (high basal Akt activity) and DU145 cells (low 
basal Akt activity) have also shown that Akt plays an important role in regulating apoptosis 
sensitivity to MSA [17]. However, the molecular mechanism of action of MSA is still not 
fully elucidated.
PI3K/Akt pathway has been shown to be activated in numerous tumours, including lung 
cancer [18], as it is essential for cell proliferation and survival. Akt is a serine-threonine 
kinase that is regulated via activation of PI3K. Forkhead box O (FOXO) transcription factors 
are direct targets of Akt that modulate cellular differentiation, cell cycle, growth, survival, 
apoptosis, metabolism, DNA repair, resistance to oxidative stress and tumour suppressor 
pathways [19]. In mammals, FOXO1, FOXO3a and FOXO4 are ubiquitously expressed 
while FOXO6 is expressed predominantly in neural cells. As transcription factors, FOXO 
proteins activate or repress the transcription of their target genes through nuclear 
translocation regulated by post-translational modifications such as phosphorylation, 
acetylation and ubiquitination [20]. FOXO phosphorylation by Akt impairs its DNA binding 
activity and promotes its interaction with the chaperone protein 14-3-3, resulting in nuclear 
exclusion, cytoplasmic accumulation and ubiquitin-proteasome pathway-dependent 
degradation, thus promoting cell survival. In contrast, FOXO proteins are activated and 
released from 14-3-3 in the presence of oxidative stress through Jun N-terminal kinase 
(JNK) signalling [19, 21, 22]. A hallmark of most cancers where the PI3K pathway is 
hyperactivated (caused by RAS, PTEN or PI3K mutations) is inactivation of FOXO proteins 
[23]. In contrast, PI3K depletion results in a significant activation of FOXO transcription 
factors, induction of apoptosis, decrease of cell viability and G1 cell cycle arrest with 
inhibition of CDK4/6, cyclin D and accumulation of p27 [24]. Therefore, the search for 
compounds that promote activation and relocalisation of FOXO from the cytoplasm to the 
nucleus is a promising therapeutic approach for cancer treatment and prevention [25].
In this study, using A549 and U2foxRELOC cells expressing a GFP–FOXO3a fusion 
protein, we have demonstrated that MSA induces FOXO3a dephosphorylation and nuclear 
translocation. These findings provide a molecular mechanism to the cytotoxicity, apoptosis, 
ROS detoxification, cell cycle arrest and metabolic changes observed in A549 cells and 
implicate FOXO3a as a relevant mediator of MSA antitumour effects.
Moreover, since it has been reported that the antitumour effects of cisplatin are enhanced 
when it is combined with FOXO nuclear export inhibitors [26–29] and that MSA 
synergistically sensitised cancer cells in combination with certain chemotherapeutic drugs 
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[30, 31], we hypothesised that combined treatment of MSA with cisplatin could be a 
promising new strategy in cancer therapy.
2. Methods
All products were purchased from Sigma-Aldrich Co (St Louis, MO, USA), unless 
otherwise specified.
2.1. Chemicals
MSA was supplied by Dr Fan (University of Kentucky, KY, USA). Sodium selenite was 
purchased from Sigma-Aldrich. Stock solutions of 10 mM were prepared with Dulbecco’s 
Phosphate Buffer Saline (PBS). The PI3K inhibitor LY294002 was purchased from 
Calbiochem (San Diego, CA, USA), antibiotic (10 000 U mL−1 penicillin, 10 mg mL−1 
streptomycin), PBS, Trypsin EDTA solution C (0.05% trypsin –0.02% EDTA) from 
Biological Industries (Kibbutz Beit Haemet, Israel) and Fetal Bovine Serum (FBS) from 
Invitrogen (Carlsbad, CA, USA).
2.2. Cell culture
Human lung carcinoma A549 cells (ATCC, Manassas, VA, USA) were grown in RPMI-1640 
medium with L-glutamine and 10 mM D-Glucose prepared following the manufacturer’s 
instructions. Human osteosarcoma stably transfected U2foxRELOC cells (a gift from Dr 
Wolfgang Link), human osteosarcoma U2OS cells, human large cell lung cancer NCI-H460 
cells, human ovary adenocarcinoma OVCAR3 cells, human embryonic kidney 293 
(HEK293) cells and adipocyte-like differentiated 3T3-L1 cells (ATCC) were grown in 
DMEM with L-glutamine and 25 mM D-Glucose. Human colorectal carcinoma HCT116 
cells (ATCC) were cultured in DMEM:HAM F12 (1:1) with L-glutamine and 12.5 mM D-
Glucose. Human breast adenocarcinoma MCF7 cells (ATCC) were cultured in MEM 
medium without phenol red (Gibco, Thermo Fisher Scientific Inc., Waltham, MA, USA) 
containing 10 mM D-glucose, 2 mM L-glutamine, 1 mM pyruvate (Biological Industries), 
0.01 mg mL−1 insulin and 1% non-essential aminoacids (Biological Industries). Media were 
supplemented with 10% heat-inactivated FBS, penicillin (50 U mL−1) and streptomycin (50 
μg mL−1). U2foxRELOC cells, which express a resistance to Geneticin, were incubated with 
G418 (Gibco) at 100 μg mL−1. 3T3-L1 pre-adipocyte cells were grown in DMEM with 0% 
FBS, 10% NCS and 0.5% streptomycin/penicillin. Cells were incubated at 37°C in a 
humidified atmosphere with 5% CO2.
2.3. 3T3-L1 differentiation
Pre-adipocyte 3T3-L1 cells were seeded in 96-well-flat-bottomed microtitre plates. Medium 
was changed two days after confluence with DMEM containing 0% NCS, 10% FBS and 
induction cocktail (250 μM isobutylmethylxanthine, 1 μM dexamethasone and 0.98 μM 
insulin). After 72 h, medium was replaced with 10% FBS DMEM containing 0.98 μM 
insulin and cells were incubated for 72 h. Then, medium was replaced with 10% FBS 
DMEM. Cells were fully differentiated into adipocytes within 48 h and cell viability assay 
was performed on them.
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2.4. Cell growth inhibition
The assay was performed using a modified method described by Mosmann [32]. Increasing 
concentrations of the inhibitor were added in sextuplicate in 96-well-flat-bottomed 
microtitre plates where 2×103 A549 cells/well had been seeded 24 h before. MSA was added 
to 3T3-L1 cells once the differentiation process was completed. MSA was depleted after >24 
h of treatment, so media was refreshed every day. After 24, 48 or 72 hours, 1 mg mL−1 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in PBS was added at a 
final concentration of 0.5 mg mL−1. After 1 hour, supernatant was removed and the 
formazan product was dissolved in 100 μL of dimethyl sulfoxide (DMSO). The absorbance 
was measured on an ELISA plate reader (Tecan Sunrise MR20-301, TECAN, Salzburg, 
Austria) at 550 nm. Concentrations that caused 50% of inhibition of cell growth (IC50) were 
calculated using Graphpad Prism 6 software (La Jolla, CA, USA).
2.5. Cell cycle analysis
5×104 A549 cells/well were seeded in 6-well plates and treated 24 hours later with MSA for 
24, 48 and 72 hours. Both adherent and detached cells were collected by centrifugation after 
trypsinisation, resuspended in 0.5 mL PBS and added dropwise to 4.5 mL 70% (v/v) cold 
ethanol. Cells were stained in PBS containing 50 mg mL−1 propidium iodide (PI), 0.2 mg 
mL−1 DNAse free RNAse (Roche, Basel, Switzerland) and 0.1% Triton X-100. 
Fluorescence-activated cell sorter (FACS) analysis was carried out at 488 nm in an Epics XL 
flow cytometer (Coulter Corporation, Hialeah, FL, USA). Data of 1×104 cells were collected 
and analysed using Multicycle program (Phoenix Flow Systems, San Diego, CA, USA). All 
experiments were performed three times with three replicates per experiment.
2.6. Apoptosis assay
Cells were seeded and treated as described in the cell cycle analysis assay. After 
centrifugation, cells were washed and resuspended in binding buffer (10 mM Hepes pH 7.4, 
140 mM sodium chloride, 2.5 mM calcium chloride). Annexin V coupled with fluorescein 
isothiocyanate (FITC) was added according to the Annexin V-FITC kit (Bender System 
MedSystem, Viena, Austria). Following 30 min of incubation at room temperature in 
darkness, PI was added at 20 μg mL−1 1 min before FACS analysis. Experiments were 
performed in triplicate and repeated three independent times. Data from 2×104 cells were 
collected and analysed in each experiment.
Apoptosis was also assessed using the membrane-permeable fluorescent dye bisbenzimide 
Hoechst. After 24 h in the absence or presence of 72hIC50 MSA, cells were harvested by 
mild trypsinisation, collected by centrifugation and fixed with 3.7% paraformaldehyde for 
10 minutes at −20°C. Cells were washed with PBS, 0.5% Triton X-100 was added for 5 min 
at 4°C and cells were stained with 50 ng mL−1 Hoechst 33342 dye for 15 min before placing 
them onto slides and mounting the coverslips with Mowiol 4–88. Chromatin condensation 
was visualised by fluorescence microscopy.
2.7. Single Cell Gel Electrophoresis (SCGE)
3×104 A549 cells/well were seeded in 6-well plates and treated the next day with 72hIC50 
MSA, hydrogen peroxide 100 μM (positive control) and vehicle (negative control). After 24, 
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the comet assay was carried out according to Tice et al. [33]. Briefly, 6×105cells mL−1 were 
mixed with 140 μL of 1% low-melting-point agarose and 70 μL were spread onto pre-coated 
microscope slides (1% of normal-melting-point agarose). Glass cover slips (Menzel-Glaser, 
Braunschweig, Germany) were placed on the gels, which were allowed to set at 4°C. Then, 
cover slips were removed and cells embedded in agarose were lysed for 1 hour by 
immersion in 2.5 M NaCl, 100 mM Na2-EDTA, 10 mM Trizma-HCl (pH 10) and 1% Triton 
X-100 at 4°C. The slides were placed on a horizontal gel electrophoresis tank and the DNA 
was allowed to unwind for 40 min in freshly prepared alkaline electrophoresis buffer (300 
mM NaOH and 1 mM Na2-EDTA, pH > 13). Electrophoresis was carried out in the same 
buffer for 30 min at 25 V in an ice bath condition. The slides were rinsed 3×5 min with 400 
mM Trizma (pH 7.5) to neutralise the excess alkali, washed in water (10 minutes), stained 
with 25 μL of 4,6-Diamidino-2-phenylindole (DAPI) (Invitrogen) and covered with a cover. 
DAPI stained nuclei were evaluated with a Nikon Eclipse TE 300 fluorescence microscope 
(Nikon, Tokyo, Japan). A total of 100 comets on each gel were visually scored and classified 
as belonging to one of five classes according to the tail intensity. Each comet class was given 
a value between 0 (undamaged) and 4 (maximum damage). Total score was calculated by the 
following equation: (percentage of cells in class 0×0) + (percentage of cells in class 1×1) + 
(percentage of cells in class 2×2) + (percentage of cells in class 3×3) + (percentage of cells 
in class 4×4). Consequently, the total score was in the range from 0 to 400. Experiments 
were performed in triplicate.
2.8. [U-13C]-glucose tracer experiments
A549 cells were seeded in 10 cm plates and grown in the RPMI medium as described above 
for 24–36 h before the medium was changed to the RPMI medium with dialysed FBS and 
[U-13C]-glucose, and in the absence (Control) or presence of 5 μM MSA. Cells in the tracer 
medium were grown for another 24 hours before harvest by trypsinisation, followed by 2 
washes in excess cold PBS to remove medium components. The final cell pellet obtained 
from spin at 1700 g, 4°C for 5 min was flash-frozen in liquid N2 before extraction with ice-
cold 10% trichloroacetic acid, as described previously [34]. The polar extracts were 
aliquoted and lyophilised for analysis by GC-MS and 1D 13C-edited HSQC NMR at 14.1 T, 
20°C using a 5 mm HCN triple resonance cold probe (Agilent Technologies, Santa Clara, 
CA). For GC-MS analysis, the extracts were derivatised in MTBSTFA before analysis, and 
for NMR analysis, the extracts were dissolved in 100% D2O, as described previously [35].
2.9. A549 transient transfection with FOXO3a-GFP reporter plasmid
A549 cells were grown on the surface of cover slips (Menzel-Glaser, Braunschweig, 
Germany) placed in 6-well plates. When confluence reached 80%, cells were transiently 
transfected with a previously incubated (30 min) mix containing 2 μg of the GFP-FOXO3a 
reporter plasmid and 2 μL of X-tremeGENE HP reagent (Roche) in 200 μL medium.
2.10. FOXO translocation assay
24 hours after seeding U2foxRELOC cells in 6-well plates containing cover slips or 21 
hours after transfection in the case of A549 cells, media were replaced with media 
containing MSA, sodium selenite, LY294002 20 μM (positive control) or vehicle (negative 
control). After 6 hours of incubation, media were replaced with fresh media containing 1 μM 
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CellTracker Red (Invitrogen) and incubated for 10 minutes. Then, media were removed and 
the cover slips containing the cells were washed 3×5 min with PBS, fixed with 
paraformaldehyde for 15 minutes and washed again 3×5 min with PBS containing 20 mM 
glycine. The cover slips were then mounted on slides using 20 μL ProLong Gold 
(Invitrogen). After 16 h, the slides were visualised in a TCS SPE Leica confocal microscope 
(Leica Microsystems, Wetzlar, Germany) and the intensity of the GFP fluorescence in nuclei 
and cytoplasm was measured from a minimum of 50 random cells per condition using 
ImageJ software (public domain National Institutes of Health, USA, http://rsbweb.nih.gov/
ij/).
2.11. Time course relocalisation assay and data analysis
The U2foxRELOC-based assay was performed as described previously [36]. All liquid 
handling for compound treatment, washing, fixing and staining steps was performed by a 
robotic workstation [37]. Briefly, 1×105 cells mL−1 were seeded in black-walled clear-
bottomed 96-well microplates (BD Biosciences, San Jose, CA, USA) in a final volume of 
200 μL/well using a multidrop automatic dispenser. After 12 h, cells were treated with 5 μM 
MSA for 1.5, 3, 6, 11 or 24 hours and 10 μM LY294002 (positive control) and vehicle 
(negative control) for 1.5 hours. Cells were washed with PBS, fixed in paraformaldehyde, 
washed again and stained with DAPI for 20 min at room temperature to define the nucleus. 
Assay plates were read on the BD Pathway 855 Bioimager (BD Biosciences) equipped with 
a 488/10 nm EGFP excitation filter, a 380/10 nm DAPI excitation filter, a 515 LP nm EGFP 
emission filter and a 435 LP nm DAPI emission filter. Images were acquired in the DAPI 
and GFP channels of each well by using 20Q dry objective. Data was exported from the BD 
Pathway Bioimager as text files and imported into the data analysis software BD Image Data 
Explorer (BD Biosciences) for processing. Cells presenting nuclear accumulation of the 
fluorescent reporter above 60% of the signal obtained from wells treated with 10 μM 
LY294002 were considered as hits.
2.12. Total protein extraction
3×105 A549 cells per well were seeded in 6-well plates and treated the next day with MSA, 
sodium selenite, LY294002 or vehicle at the specified concentrations for 6 and 24 hours. At 
the end of the treatment, cells were washed twice with ice-cold PBS, incubated for 30 min 
on ice in lysis buffer containing 20 mM Trizma Base (pH 7.5), 1 mM dithriothreitol, 1 mM 
EDTA, 0.0002% Triton X-100, 0.5 mM sodium deoxycholate, 0.4 mM PMSF, 1% protease 
inhibitor cocktail and 1% phosphatase inhibitor cocktail (Thermo Scientific, Thermo Fisher 
Scientific Inc., Waltham, MA, USA). Cells were scraped, sonicated and centrifuged at 16 
000 g for 20 min at 4°C. Supernatants were recovered and the protein content was quantified 
by the bicinchoninic acid (BCA) kit (Pierce Biotechnology, Rockford, IL, USA).
2.13. Cytosolic and nuclear protein extracts
A549 cells were cultured and treated as described in Total protein extraction section. In this 
case, cells were incubated for 10 min on ice with hypotonic buffer containing 20 mM 
HEPES (pH 7.6), 10 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 20% (v/v) glycerol, 0.1% 
(v/v) Triton X-100, 1% protease inhibitor cocktail and 1% phosphatase inhibitor cocktail. 
Cells were scraped and pipetted into cooled eppendorf tubes and then centrifuged at 1000 
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rpm in a swinging-bucket centrifuge at 4°C. Supernatant was the cytoplasmic extract and the 
pellet contained the nuclei. To extract the nuclear proteins, the pellet was resuspended in five 
times its volume with hypertonic buffer (hypotonic buffer adding 500 mM NaCl), rocked for 
one hour at 4°C and spinned at maximum speed at 4°C for 5 min. The nuclear extract was 
the supernatant. Both cytosolic and nuclear extracts were assayed for protein concentration 
using the BCA kit.
2.14. Western blot analysis
An equal volume of protein was size-separated by electrophoresis on SDS-polyacrylamide 
gels and electroblotted onto polyvinylidene fluoride transfer membranes (PVDF) (Bio-Rad 
Laboratories, Hercules, CA, USA). After 1 h of blocking at room temperature with 5% skim 
milk in PBS 0.1% Tween, blots were incubated with the specific primary antibodies 
overnight at 4°C. Then, membranes were treated with the appropriate secondary antibody for 
1 h at room temperature. All blots were treated with Immobilon ECL Western Blotting 
Detection Kit Reagent (EMD Millipore, Billerica, MA, USA) and developed after exposure 
to an autoradiography film (VWR International, Radnor, PA, USA). The primary antibodies 
used were Phospho-Akt (#9271), Akt (#9272), Phospho-mTOR (#5536) and procaspase 3 
(#9662) from Cell Signaling (Beverly, MA, USA); FOXO3a (#06-951) from Upstate (EMD 
Millipore); Phospho-FOXO3a (sc-101683), Phospho-JNK (sc-6254), FOXM1 (sc-500), Bax 
(sc-493), CDK4 (sc-260), CDK6 (sc-177), ERK 2 (sc-154) and Lamin B (sc-6217) from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA); Phospho-PRAS40 (#44-1100) from 
BioSource International (Camarillo, CA, USA); PARP (#556493) and cytochrome c 
(#556433) from BD Pharmingen (BD Biosciences); p27 (#610242) from BD Transduction 
Laboratories (BD Biosciences) and β-actin (#69100) form MP Biomedicals (Santa Ana, CA, 
USA).
2.15. FOXO1 gene expression. RNA extraction, quantification, retrotranscription and 
Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR)
RNA was isolated from frozen plates using Trizol reagent (Invitrogen) following the 
manufacturer’s instructions. Briefly, Trizol cell homogenates were mixed with chloroform 
and centrifuged, obtaining an aqueous phase and an organic phase. In order to precipitate 
RNA, cold isopropanol was added in the aqueous phase and centrifuged at 12 000 g for 15 
min at 4°C. RNA was purified by several cold 75% ethanol washes and finally resuspended 
in RNAse free water. RNA was quantified using a Nanodrop (ND 1000 V3.1.0, Thermo 
Fisher Scientific Inc.). Reverse transcription was carried out with 1 μg RNA at 37°C for 1 h 
with the following reagents: Buffer 5x (Invitrogen), DTT 0.1 M (Invitrogen), Random 
Hexamers (Roche), RNAsin 40 U μL−1 (Promega, Fitchburg, WI, USA), dNTPs 40 mM 
(Bioline, London, UK), M-MLV-RT 200 U μL−1 (Invitrogen). Gene expression analysis was 
performed on an Applied Biosystems 7500 Real-Time PCR System according to the 
manufacturer’s protocol, using Taqman gene specific sequences (FOXO1: Hs01054576_m1, 
Applied Biosystems, Thermo Fisher Scientific Inc.). Reactions were performed in 20 μL 
volume, using 9 μL of the cDNA mixture and 11 μL of the specific Taqman in Master Mix 
(Applied Biosystems). Real-Time PCR was conducted according to the following 
parameters: an initial incubation at 50°C for 2 min, a denaturalisation at 95°C for 10 min, 
followed by 40 cycles at 95°C and 60°C for 15 s and 1 min, respectively. Expression was 
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quantified by ΔΔCt method using Cyclophilin A (PPIA: Hs99999904_m1, Applied 
Biosystems) as reference gene.
2.16. Determination of Intracellular Reactive Oxygen Species (ROS) levels
A549 cells were grown on 6-well plates to 70% confluence, washed once with warm PBS, 
and incubated with 5 μM 2′-7′-dichlorodihydrofluorescein diacetate (H2DCFDA, Invitrogen) 
in PBS supplemented with 5.5 mM glucose. After 30 min at 37°C, PBS was replaced with 
complete culture medium and incubated for another 50 min at 37°C. Finally, cells were 
trypsinised and resuspended thoroughly with 0.4 mL of PBS, H2DCFDA (50 μM) and PI (20 
μg mL−1). Intracellular internalised probe reacts with ROS and emits fluorescence when 
excited at 492 nm. Emitted fluorescence was recorded by flow cytometry at 520 nm using an 
Epics XL flow cytometer (Coulter Corporation, Hialeah, FL, USA). Data of DCF 
fluorescence concentrations from 1×104 PI negative cells were collected and analysed using 
Multicycle program (Phoenix Flow Systems, San Diego, CA, USA).
2.17. Stable shRNA cell line generation
U2OS and HEK293 stable FOXO3a knockdown cell lines were generated by Effectene 
(Qiagen, Hilden, Germany) reagent-mediated transfection with three different FOXO3a 
shRNA constructs originated from the Netherlands Cancer Institute (NKI) shRNA library 
[38]. FOXO3a shRNA sequences FOXO3a KD#1 
(GCAGGCCTCATCTCAGAGCTCTCTTGAAGCTCTGAGATGAGGCCTGC), FOXO3a 
KD#2 (CTGCGACGGCTGACTGAAATCTCTTGAATTTCAGTCAGCAGTCGCAG) and 
FOXO3a KD#3 
(CCTGATGGGGGAAANANCTCTCTTGAANCTCTGANATGANGCCTGC) were cloned 
into pRetroSuper vector (NKI, Amsterdam, Netherlands). Empty pRetroSuper vector was 
used for control cells (Ctrl). Cells were selected in complete medium containing 1 μg mL−1 
puromycin.
2.18. Data analysis and statistical methods
Experiments were carried out at least in triplicate and repeated three times. To evaluate the 
effects of combined drug treatments the multiple drug-effect analysis of Chou–Talalay [39] 
was used with the CompuSyn software (ComboSyn, Inc., Paramus, NJ, USA). MSA 
interactions with cisplatin and carboplatin were quantified by determining the Combination 
Index (CI), where CI<1, CI=1, and CI>1 indicate synergism, additivity, and antagonism, 
respectively. All data are expressed as mean ± standard deviation (SD). Statistical analyses 
were performed using Statgraphics statistical package (Statgraphics Centurion XVI, 
StatPoint technologies Inc., Warrenton, VA, USA). Control and treatment measurements 
were compared using Kruskal-Wallis, ANOVA and two-tailed independent sample Student’s 
t tests. Differences were considered to be significant at p < 0.05.
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3. Results
3.1. MSA inhibits cell proliferation and causes G1 arrest in human lung carcinoma A549 
cells
The effect of MSA on human lung carcinoma A549 cell proliferation was examined using 
the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) colorimetric 
viability assay. Significant dose-dependent growth inhibition was observed in this cell line 
after treatment with 10 different concentrations of MSA for 24, 48 and 72 h (Figure 1A).
The MSA concentrations required for achieving a 50% growth inhibition on A549 cells after 
24, 48 and 72 h of treatment (24hIC50, 48hIC50 and 72hIC50) were 2.2 ± 0.3 μM, 1.6 ± 0.2 and 
1.3 ± 0.1 μM, respectively.
Flow cytometric analyses of cell cycle distribution of A549 cells that had been exposed 
to 72hIC50 MSA showed an increase of the G1 population at 24, 48 and 72 h of treatment as 
compared to control cells (increasing by 41% at 72 h). With the same treatment, a 
concomitant decrease was also observed in the percentage of cells in the S phase after 24, 48 
and 72 h of treatment with respect to the untreated cells (38% decrease at 72 h), suggesting a 
G0/G1 arrest (Figure 1B). A reduction in the percentage of cells in the G2 phase was also 
observed at all times.
The interphase cyclin-dependent kinases CDK4 and CDK6 control cell cycle re-entry and 
progression through G1 phase. In response to mitogenic stimuli, CDK4/6-cyclin D 
complexes phosphorylate the retinoblastoma (RB) protein family leading to their partial 
inactivation and relieving the transcriptional repression mediated by the RB-E2F complex 
[40]. Accordingly, MSA-induced cell cycle arrest could result from negative regulation of 
CDK4/6-cyclin D complexes. To test this idea, CDK4 and CDK6 protein expression was 
analysed after incubating A549 cells with 5 μM MSA for 6 h. A significant decrease in the 
protein levels of CDK4/6 was observed in MSA-treated cells (Figure 1C).
To determine whether the concentrations of MSA used in the present study can acidify the 
media, we measured the pH values before and after the addition of MSA at 1.3 and 5 μM 
final concentrations. We also assessed the pH values after the addition of acetic acid, which 
is a weak acid with an acid dissociation constant (Ka) of 1.8·10−5 and a similar molecular 
structure as MSA. While the addition of acetic acid at 5 μM decreased the pH of the medium 
by 0.5 units, the same concentration of MSA did not cause any significant effects. Therefore, 
we conclude that the media were not acidified by the doses of MSA used in this study.
3.2. MSA induces apoptosis in A549 cells
Apoptosis was assessed in A549 cells after 24, 48 and 72 h of treatment with 1.3 μM MSA 
(72hIC50 for growth inhibition). FACS analysis using annexin V-FITC staining and PI 
accumulation was performed to differentiate non-apoptotic cells (annexin V− and PI−), early 
apoptotic cells (annexin V+ and PI−) and late apoptotic/necrotic cells (PI+).
To determine if MSA effects were specific or general to other selenium compounds, sodium 
selenite was included in our analysis (Figure 2A). MSA treatment for 24 h caused no 
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significant effect on A549 cell apoptosis, while at 48 and 72 h, MSA exposure generated an 
increase in early apoptotic cells. In contrast, the apoptotic effect of sodium selenite was 
visible at 24 h and greatly enhanced at 48 and 72 h (reaching around 40% for early apoptotic 
cells) whereas the percentage of late apoptotic and necrotic cells remained constant at the 
three time points. Therefore, the extent of apoptosis caused by MSA was much reduced 
compared to that induced by sodium selenite, which can be due to different mechanisms of 
apoptosis activation.
Apoptotic cells undergo a series of characteristic morphological changes, such as shrinkage 
of the cell, chromatin condensation, apoptotic body formation and internucleosomal 
fragmentation of genomic DNA [41]. In order to evaluate DNA integrity, a single-cell gel 
electrophoresis was performed (Comet assay). Single strand break of DNA was observed 
after 24 h treatment with 1.3 μM MSA (Figure 2B). Total Comet score of treated and 
untreated cells were 199 and 74, respectively. The presence of apoptotic bodies following 72 
h MSA treatment at 72hIC50 concentration was detected by Hoechst 33342 staining (Figure 
2C). Other typical apoptotic features such as rounding, shrinkage, detachment and loss of 
contact with adjacent cells were observed in MSA-treated cells (Figure 2D) using an 
inverted phase contrast microscope.
Activation of the caspase pathway plays an important role in apoptosis. Caspases are 
constitutive cysteine proteases that are normally present as inactive proenzymes. Their 
enzymatic activity is induced during apoptosis in a self-amplifying cascade. Cleaved 
upstream caspases (caspases 2, 8, 9 and 10) activate effector caspases (caspases 3, 6 and 7) 
by proteolysis initiating the apoptotic cascade of events [41]. The intrinsic apoptosis 
pathway involves the release of cytochrome c into cytosol and the formation of the 
apoptosome complex by association with APAF-1. This complex activates caspase 9 which 
in turn cleaves procaspase 3, implicated in the proteolysis of poly (ADP-ribose) polymerase 
(PARP).
To elucidate the mechanisms involved in MSA or sodium selenite-mediated induction of 
apoptosis in A549 cells, whole-cell lysates were extracted and Western blot analyses were 
performed. The effects of LY294002, a known PI3K inhibitor [42], were also assessed. As 
shown in Figure 2E, incubation with 5 μM MSA enhanced the expression of pro-apoptotic 
Bax and cytosolic cytochrome c, decreased the level of procaspase 3 and caused PARP 
cleavage. Sodium selenite 5 μM treatment induced changes in the same direction but to a 
significantly lower extent (sodium selenite 72hIC50 in A549 cells is 5.5 ± 0.4 μM, data not 
shown).
3.3. MSA blocks glycolysis, TCA cycle and nucleotide biosynthesis
The effect of MSA on A549 cell metabolism was examined using the Stable Isotope-
Resolved Metabolomics (SIRM) approach [43–45]. A549 cells were treated with 
uniformly 13C-labeled glucose ([U-13C]-glucose) in the absence (Control) or presence of 5 
μM MSA for 24 h. The glucose transformation products were analysed by 1D HSQC NMR 
and GC-MS, as shown in Figure 3. MSA-treated A549 cells had reduced synthesis of 13C 
labelled lactate (glycolytic product), malate, aspartate, glutamate, citrate (TCA cycle 
metabolites), as well as adenine and uracil nucleotides (with the ribose unit derived from the 
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PPP), relative to untreated A549 cells. These results suggest that MSA attenuates the activity 
of glycolysis, TCA cycle, PPP and/or nucleotide biosynthesis.
3.4. MSA causes nuclear translocation of FOXO3a in U2foxRELOC cells
Taking into account the arrest of cell cycle (G1), apoptosis induction, the metabolic effects 
of MSA on A549 cells and their correlation with those described for the PI3K inhibition 
[14], and the observed effects of MSA on PI3K signalling, we evaluated the effect of MSA 
on FOXO factors known to be the major transcriptional downstream effecter proteins of the 
PI3K/Akt signal transduction pathway [46]. As the activity of FOXO factors is mainly 
regulated by their subcellular localisation [47], we first investigated if MSA induced FOXO 
nuclear translocation. To this end we used U2foxRELOC cells, a previously established cell 
system based on U2OS osteosarcoma cells that stably express a GFP–FOXO3a reporter [36, 
48, 49].
In order to select the optimal MSA concentration for analysing its effects on FOXO 
translocation, the MSA 72hIC50 in U2foxRELOC cells was determined by incubating the 
cells with 10 different concentrations of MSA for 72 h and performing colorimetric viability 
assay. The values for dose-dependent growth inhibition were similar to the results obtained 
for A549 cells (Figure 4C). We next analysed the spatio-temporal kinetics of FOXO nuclear 
translocation upon MSA treatment. We exposed U2foxRELOC cells to 5 μM MSA for 1.5, 
3, 6, 11 and 24 hours and determined subcellular localisation of the fluorescent FOXO 
reporter protein. MSA treatment induced GFP-FOXO3a nuclear translocation from 1.5 to 24 
h, reaching a maximum effect between 3 and 6 hours (data not shown).
With the assay conditions optimised, U2foxRELOC cells were treated with 1.3 and 5 μM 
MSA for 6 h and the subcellular localisation of GFP-FOXO3a was monitored by confocal 
microscopy. Vehicle was used as a negative control and LY294002 (20 μM) as a positive 
control. As shown in Figure 4A, GFP-FOXO3a was present in the cytosol of untreated cells 
as well as in the nucleus, whereas in MSA- and LY294002-incubated cells GFP-FOXO3a 
was localised almost exclusively in the nuclei. The percentage of cells in which GFP-
FOXO3a nuclear intensity was at least 3.5 times higher than GFP-FOXO3a cytoplasmic 
intensity was less than 6% for control cells, more than 95% for LY294002-treated cells and 
more than 94% for MSA-treated cells (at both concentrations) (Figure 4B). To determine 
whether FOXO3a nuclear translocation was specifically driven by MSA or was a general 
characteristic of selenium compounds, U2foxRELOC cells were also incubated with sodium 
selenite at the same concentrations as MSA. The intracellular distribution of GFP-FOXO3a 
remained unaltered in the presence of sodium selenite (Figure 4A). These results support our 
hypothesis that MSA specifically induces FOXO3a nuclear translocation.
3.5. MSA induces GFP-FOXO3a nuclear translocation and increases nuclear FOXO3a in 
A549 cells
To further confirm our hypothesis and test if the translocation effect of MSA is also relevant 
for lung cancer cells, the effect of MSA on FOXO3a in A549 cells was analysed. To this 
end, we transiently transfected GFP-FOXO into A549 cells and exposed them to MSA. 
Figures 5A and 5B illustrate the results obtained after 6 h incubation with 5 μM MSA, 20 
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μM LY294002 or vehicle. MSA induced nuclear accumulation of FOXO3a in A549 cells, 
resulting in over 90% of cells exhibiting nuclear fluorescence intensity at least 1.5 times 
greater than cytoplasmic fluorescence intensity, compared to less than 2.5% of cells for the 
control conditions. To confirm the nuclear translocation of endogenous FOXO3a in non-
transfected A549 cells in response to MSA treatment, Western blot assays of cells incubated 
in the same conditions were performed. As shown in Figure 5C, MSA causes an increase in 
nuclear FOXO3a concentration and a decrease in the levels of cytoplasmic phosphorylated 
FOXO3a at the Ser253 residue (a known Akt phosphorylation site), consistent with our 
aforementioned results.
Since it is been described that FOXO1 transcription is stimulated by FOXO3a in a positive 
feedback loop [50, 51], the effect of MSA on FOXO1 mRNA levels was analysed. Cells 
were incubated with 5 μM MSA for different time periods from 1 h up to 24 h. Induction of 
FOXO1 expression was detected from 2 h to 24 h and increased in a time-dependent manner 
(Figure 5D).
To validate the results obtained with confocal microscopy of U2foxRELOC cells treated 
with MSA and sodium selenite, the levels of active FOXO3a in non-transfected A549 cells 
were analysed by Western blot. As shown in Figure 6, MSA induced FOXO3a expression 
while sodium selenite caused its inhibition. To confirm this observation, FOXM1 protein 
expression was examined, as previous studies have reported that FOXO3a is a negative 
regulator of FOXM1 at the transcriptional level [52, 53]. In agreement with these 
observations and further supporting MSA’s mode of action through FOXO3a activity, MSA 
treatment significantly decreased FOXM1 expression while sodium selenite enhanced the 
level of this transcription factor (Figure 6).
In order to identify the mechanisms involved in FOXO subcellular redistribution, changes in 
FOXO-regulating signal transduction pathways in response to MSA treatment were studied. 
It was previously reported that cell cycle arrest induced by FOXO proteins is mediated by 
enhanced transcription and protein expression of the cyclin-dependent kinase inhibitor p27 
[54, 55] and reduced protein expression of cyclins D1 and D2 [56]. Both cases result in an 
impaired capacity of CDK4 and CDK6 to hyperphosphorylate the RB protein family, 
leading to G1 arrest [40]. Moreover, while FOXO3a has been reported to induce the 
transcription of p27, PI3K/Akt pathway is known to suppress its expression in order to 
proceed with cell cycle [57]. To investigate whether MSA-induced G1 cell cycle arrest is 
associated with Akt and FOXO signalling, p27 and phosphorylation of Akt on Ser 473 status 
were analysed by Western blot. Six-hour treatment with MSA (at both 1.3 and 5 μM) 
significantly suppressed Akt phosphorylation without affecting its total protein level (Figure 
6). These results suggest that FOXO3a dephosphorylation and nuclear accumulation in 
response to MSA are mediated by Akt inactivation. The PI3K inhibitor LY294002 showed 
the same behaviour as MSA while sodium selenite increased Akt phosphorylation in a dose-
dependent manner. The overactivation of Akt mediated by sodium selenite could account for 
the depletion in FOXO3a levels observed (Figure 6). PRAS-40, an Akt substrate, followed 
the same phosphorylation pattern, further supporting our hypothesis (Figure 6). mTOR 
pathway was downregulated by MSA as phosphorylated mTOR levels were reduced 
significantly after MSA treatment while sodium selenite activated this signalling pathway by 
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increasing P-mTOR level. Dephosphorylation of Akt and FOXO activation preceded the 
caspase-mediated apoptosis and the transcription of FOXO3a target genes such as p27 
(Figure 6). As expected, p27 levels were notably increased after exposure to 5 μM MSA and 
20 μM LY294002 for 24 h, even though p27 level was only slightly enhanced by exposure to 
1.3 μM MSA. These data corroborate with previous results that showed MSA and sodium 
selenite inducing distinct biochemical and cellular responses [7, 58, 59].
3.6. MSA elicits ROS detoxification
FOXO proteins have been reported to induce detoxification of reactive oxygen species 
(ROS) by up-regulating free radical scavenging enzymes, including manganese superoxide 
dismutase and catalase [25]. FOXO transcription factors regulate two aspects of cellular 
resistance to stress: repair of damages caused by ROS and detoxification of ROS [19]. Given 
that MSA causes FOXO3a translocation to the nucleus, we measured ROS levels in A549 
cells. The results show that 1.3 μM MSA caused a significant decrease in the levels of ROS 
at 24 and 48 h (Figure 7). This decrease is consistent with the increased cellular free thiol 
levels observed by Poerschke et al. [60] after 24 h MSA incubation. Cells incubated with 
MSA for 72 h had similar ROS level to control cells. In contrast, sodium selenite inhibited 
ROS production at 24 h but enhanced it at 48 and 72 h.
Previous studies described the role of JNK as a FOXO activator mediating the 
phosphorylation of 14-3-3 proteins, thus releasing FOXO factors and trigging their nuclear 
relocalisation [61–63]. As shown in Figure 6, MSA incubation resulted in an increase in P-
JNK, which is consistent with FOXO activation by Akt dephosphorylation. Sodium selenite 
enhancement in P-JNK levels could be a consequence of selenite-induced ROS production 
since JNK cascade can be independently activated by environmental stresses [64].
3.7. FOXO3a knockdown attenuates MSA effects
In order to confirm the role of FOXO3a as a mediator of MSA antitumour effects, we stably 
silenced FOXO3 in two different cell lines using shRNA vectors. We established U2OS and 
HEK293 cells that stably expressed three different hairpin sequences and validated the 
efficiency of FOXO3a knockdown by Western blot. The results revealed that FOXO3a KD#1 
construct exhibited the strongest knockdown effect, followed by FOXO3a KD#2 (Figure 
8A). Hence, the U2OS cell lines transfected with these two constructs and the FOXO3a 
KD#1 HEK293 cell line were selected to perform the following experiments.
We incubated Ctrl (empty vector) and FOXO3a knockdown cells with 1 μM MSA or vehicle 
(PBS) and measured cell proliferation, cell cycle and apoptosis after 72 h (Figure 8B–G), 
and ROS after 48 h treatment (Figure 8H–I). The results showed that MSA effects were 
attenuated or even abolished by FOXO3a knockdown. In fact, the observed antiproliferative 
effect of MSA was significantly reduced after FOXO3a inhibition, while no differences in 
cell cycle, apoptosis and ROS levels were found between untreated and MSA-treated 
FOXO3a knockdown cells. These results further confirm that the antitumour response of 
MSA treatment is mediated by FOXO3a.
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3.8. MSA as a promising chemotherapeutic agent
Cisplatin-based therapy is a conventional chemotherapeutic treatment for cancer. However, 
its clinical efficacy is compromised by acquired resistance and dose-limiting side effects 
[65]. Consequently, the search for combination therapies and chemosensitising agents to 
cisplatin is essential for improving its treatment outcome. Given that previous studies 
reported the enhancement of cisplatin’s antitumour effects in combination with FOXO 
nuclear export inhibitors [26–29], we hypothesised that combined treatment of MSA with 
cisplatin could be a promising new strategy in cancer therapy.
To quantify the synergy of dose-dependent effect on cell viability, we used the Combination 
Index (CI) equation of Chou and Talalay [39]. We examined the synergistic effects of MSA 
and cisplatin in A549, HCT116 (colorectal carcinoma), MCF7 (breast adenocarcinoma) and 
OVCAR3 (ovary adenocarcinoma) cells which are considered to present cisplatin-resistance, 
exhibiting IC50 values higher than 10 μM [66] (http://www.cancerrxgene.org/translation/
Drug/1005). The combination of MSA and cisplatin treatment in a wide dose range showed 
a significant synergism in the antiproliferative effects with a CI<1 in each tested cell line 
(Table 1).
In addition, we studied the synergism of MSA and carboplatin, a derivative of cisplatin 
commonly used in conventional chemotherapy with similar efficacy, in the same cell lines. 
Likewise, the combination of MSA and carboplatin treatment in a wide dose range exhibited 
a synergistic (CI<1) antiproliferative effect in each tested cell line (Table 2).
Compared with cisplatin or carboplatin single treatments, dosage of these conventional 
chemotherapeutics could be remarkably reduced in combination therapy with MSA to gain 
the same inhibitory effect on cell proliferation. Therefore, the synergism observed in 
HCT116, MCF7, A549 and OVCAR3 cells suggests the combined MSA / cisplatin or 
carboplatin treatment as an efficient strategy to decrease the chemotherapeutic doses and 
consequently, mitigate the overall toxicity.
In order to determine if MSA treatment obtained similar growth inhibitory results in other 
cancer cell lines, the effect of MSA on cell viability in NCI-H460 (large cell lung cancer) 
and HCT116 (colorectal carcinoma) cell lines was measured. The 72hIC50 values obtained 
were in the same range as for A549 cells, being 1.7 ± 0.2 μM and 1.9 ± 0.2 μM for NCI-
H460 and HCT116 cells, respectively (Figure 9A). To investigate if FOXO activation 
mediated by MSA is a general mechanism and not cell-dependent, HCT116 cell line was 
used to evaluate FOXO1 mRNA expression, which showed a significant increase in a time-
dependent manner beginning at 2 h with 5 μM MSA treatment (data not shown).
To test the selective cytotoxicity of MSA for cancer cells, a MTT colorimetric viability assay 
using a non-tumour non-proliferating cell line was performed. Differentiated 3T3-L1 
adipocytes were incubated for 72 h with 9 different MSA concentrations and the effect on 
cell proliferation and the 72hIC50 value were determined (Figure 8A). 72hIC50 for MSA in 
3T3-L1 cells was three to five times the value for all tumour cell lines that have been studied 
(Figure 9B), supporting MSA as a promising chemotherapeutic agent with selective 
antiproliferative effects on cancer cells.
Tarrado-Castellarnau et al. Page 15
Pharmacol Res. Author manuscript; available in PMC 2016 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
4. Discussion
Selenium is an essential trace element fundamental to human health with pivotal structural 
and enzymatic functions in selenoproteins. Selenium deficiency has been acknowledged as a 
contributing factor to a series of distinct pathophysiological conditions, including cancer. 
Several selenium compounds have shown cancer chemopreventive and chemotherapeutic 
activities in both animal models and humans [11, 67, 68]. It is important to note that both 
dose and chemical form of selenium are crucial for the antitumour activity. MSA and 
sodium selenite are among the forms with high anticarcinogenic activity while 
selenomethionine used in the SELECT trial was ineffective in cancer prevention in humans 
[11, 69, 70].
There are several in vivo studies involving dietary selenium supplementation for cancer 
therapy and prevention. The evaluation of the effects of different diets containing MSA, 
sodium selenite or selenomethionine in tumour xenografts in mice has led to the conclusion 
that MSA exhibits a superior in vivo inhibitory efficacy against human prostate and breast 
cancers over selenomethionine or sodium selenite [8, 10, 71]. Indeed, dietary 
supplementation with MSA significantly inhibits xenograft tumour growth and reduces 
angiogenesis and spontaneous metastasis [8, 10, 71–73]. Importantly, supplementation with 
MSA does not affect neither the animal body weight nor the food consumption when 
compared with control diet animals, and histological alterations in organs are not observed, 
altogether indicating a good tolerance to the used dosage of MSA without adverse side 
effects [8, 71, 72]. Moreover, MSA supplementation results in less accumulation of selenium 
both in liver and primary tumour when compared with selenomethionine, while causes no 
increment in kidney selenium levels relative to controls [8, 10, 71]. These results are 
consistent with the fact that MSA is efficiently transformed into methylselenol which in turn 
can be methylated and excreted [74]. Therefore, MSA treatment presents superior in vivo 
antitumour efficacy with good tolerance results over other selenium derivates [8, 10, 71, 72].
The fact that the molecular mechanism underlying MSA’s antitumour properties has not 
been fully elucidated is a bottle neck in designing combination therapies with MSA. In this 
study, we described that lung carcinoma A549 cells are very sensitive to MSA treatment, in 
terms of growth inhibition, cell cycle arrest in G1 phase, attenuated intracellular ROS levels 
and apoptosis. However, some studies have described selenium derivatives as pro-oxidant 
products at higher doses than those used in this study [13]. This property could be due to 
dose dependence: at low concentrations MSA could serve as an antioxidant product, while at 
higher concentrations it could act as a pro-oxidant compound [69]. The antioxidant function 
could be mediated via the synthesis of selenocysteine, which is an essential residue of 
important ROS-detoxifying selenoproteins, such as glutathione peroxidases, thioredoxin 
reductases and possibly selenoprotein P [75]. Our results suggest distinct redox modulations 
of the two selenocompounds tested and thus different mechanisms of action. Heightened 
levels of ROS generated by sodium selenite can cause damage to DNA and mitochondria, 
leading to apoptosis. Considering these and previous results [6], sodium selenite induces 
apoptosis through generation of ROS while MSA-mediated apoptosis is regulated by a 
different molecular pathway like FOXO activation.
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We have also shown that MSA induces FOXO translocation to the nucleus after 1.5 h of a 5 
μM treatment and this localisation is maintained for at least 24 h. In addition, we have 
demonstrated that FOXO translocation after 1.5 h is the early event that occurs before the 
observed molecular and metabolic effects of MSA. Moreover, we have shown that the 
inhibition of the PI3K pathway through Akt and FOXO3a dephosphorylation could be the 
molecular mechanism underlying inhibition of cell proliferation, disruption of tumour cell 
metabolic adaptations, induction of apoptosis, ROS detoxification and cell cycle arrest in 
A549 cells. Indeed, FOXO3a knockdown attenuated or even abolished the antiproliferative 
effects of MSA. It is worth noting that although MSA activity is mediated through inhibition 
of Akt, it does not have an effect on other signalling pathways such as MAPK [7].
FOXO proteins are potentially key targets for new therapeutic strategies for blocking 
tumourigenesis due to their ability to control cell cycle and promote apoptosis [76]. The 
tumour suppressor properties of FOXO factors are inhibited mostly by overactivation of their 
inhibitory signalling, in contrast to other tumour suppressors, whose activities are abrogated 
by genetic or epigenetic changes. These characteristics call for strategies on rescuing FOXO 
activity by its reactivation and targeting of its inhibitors [25]. As such, MSA is well-suited to 
serve as an anticancer agent by inhibiting the PI3K/Akt/mTOR axis and activating JNK 
signalling pathway, leading to FOXO nuclear relocalisation and restoration of its gene 
expression. Moreover, combination therapies that target PI3K/Akt pathway and promote 
nuclear FOXO retention are considered to be a promising approach to treat several tumour 
types. For example, in recent studies it has been proposed that cytotoxicity of cisplatin in 
sensitive cells can be enhanced and drug resistance in unresponsive cells reversed by using 
agents that target the PI3K/Akt/FOXO pathway in combination with cisplatin [26–29]. Our 
studies support such hypothesis as MSA both synergised with cisplatin and its derivative 
carboplatin in blocking A549, HCT116, MCF7 and OVCAR3 cell proliferation. Thus, the 
combination of MSA with either cisplatin or carboplatin could represent a promising new 
approach to lung cancer treatment in terms of reducing platinum derivatives doses or toxicity 
as well as drug resistance.
5. Conclusions
Our data support a strong antiproliferative action of MSA in the low micromolar range on 
A549 cells, which is mediated by blocking G1 progression and triggering apoptosis. These 
MSA effects are associated with the inhibition of the Akt pathway, leading to 
dephosphorylation of FOXO proteins and their nuclear translocation, which in turn activate 
the expression of FOXO target genes. The time course data suggest that FOXO 
dephosphorylation and relocalisation to the nucleus are early events that activate the 
antiproliferative response of A549 cells to MSA. By targeting the PI3K/Akt/FOXO pathway, 
MSA could synergise with cisplatin in combination therapy to reduce the commonly 
observed toxicity and resistance development of cisplatin-based chemotherapy.
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Figure 1. MSA effects on cell viability and cell cycle in A549 cells
A. Growth inhibition of MSA on A549 lung cancer cells after 24, 48 and 72 h measured by 
MTT assay. Exponentially growing cells were treated with the indicated concentration of 
MSA for 24, 48 and 72 h. The assay was carried out using six replicates and repeated three 
times. Data are represented as mean ± SD. B. Cell cycle analysis of MSA-treated cells. 
A549 cells treated for 24, 48, 72 hours with 1.3 μM MSA presented a G1 arrest. Cell cycle 
analysis was conducted after propidium iodide staining. Values represent mean ± SD and 
statistically significant differences between treated and control cells at p < 0.05 are indicated 
with an asterisk (*). C. Western blot analysis showed a significant CDK4 and CDK6 
inhibition at 6 h treatment with 5 μM MSA. Protein expression levels were quantified using 
ImageJ software and are expressed as mean band intensity normalised to β-actin and relative 
to control condition (*, p < 0.05).
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Figure 2. Apoptosis assays in A549 cells
A. Flow cytometry analysis of Annexin V-FITC staining and propidium iodide accumulation 
after exposure of A549 cells to MSA and sodium selenite at their respective 72hIC50 
concentrations for 24, 48 and 72 hours. PI staining at 488 nm is represented on the y axis 
and annexin V-FITC staining at 488 nm on the x axis. Quadrant 4 (PI–/FITC−) represents 
non-apoptotic cells, early apoptosis is shown in right bottom quadrant (PI–/FITC+) and 
quadrants 1 and 2 (PI+) depict late apoptotic/necrotic cells. Plots illustrate the percentage of 
cells in early apoptosis and late apoptosis/necrosis. Values are expressed as mean ± SD of 
three experiments in triplicate. Differences between treated and control groups were 
considered statistically significant at p < 0.05 (*). B. DAPI staining of A549 cells DNA after 
electrophoresis in agarose gel (single-cell gel electrophoresis, Comet Assay). Control 
condition treatment with vehicle showed no induction of single strand breaks while 24 h 
MSA exposure at 72hIC50 concentration caused DNA fragmentation in A549 cells. C. 
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Morphological changes in nuclei were examined after 72 h MSA treatment at 72hIC50 
concentration. Hoechst stained nuclei were evaluated with a fluorescence microscope (200 
and 400X, scale bar 3 μm) to detect increased condensation and margination of chromatin to 
the nuclear envelope and the formation of apoptotic bodies (white arrows). Apoptotic bodies 
were not observed in control condition. D. Cells were incubated with MSA, sodium selenite 
and LY294002 at the indicated concentrations for 24 h and observed using an inverted phase 
contrast microscope. E. Western blot analysis of total protein fractions of A549 cells. Protein 
expression was determined by densitometry analysis using ImageJ software and is 
represented as mean band intensity normalised to β-actin and related to untreated controls. 
MSA apoptosis activation is represented by enhancement of Bax and cytosolic cytochrome c 
expression, decrease of procaspase 3 levels and PARP cleavage (*, p < 0.05). Sodium 
selenite induced changes in the same direction but to a significantly lower extent.
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Figure 3. MSA perturbs glycolysis, TCA cycle and nucleotide biosynthesis
A549 cells were grown in 0.2% [U-13C]-glucose in the presence or absence of 5 μM MSA 
for 24 h. The polar metabolites were extracted in ice-cold 10% trichloroacetic acid and 
analysed by 1D HSQC NMR (A, acquired at 14.1 T, 20°C) and GC-MS (B). A. 
Representative 1D HSQC NMR spectrum. The abundance of the ribosyl unit of adenine 
(13C-1′-AXP) and uracil (13C-1′-UXP) nucleotides was significantly attenuated 24 h after 
MSA treatment, relative to the control treatment. B. The GC-MS analysis revealed reduced 
synthesis of TCA cycle metabolites, [2-13C]-malate (Mal), [2-13C]-aspartate (Asp), [2-13C]-
glutamate (Glu) and [2-13C]-citrate (Cit), in addition to the glycolytic product, [3-13C]-
lactate (Lac). p values < 0.05 (*) were considered statistically significant.
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Figure 4. Nuclear translocation of GFP–FOXO following MSA treatment in U2foxRELOC cells
U2foxRELOC cells stably expressing GFP–FOXO fusion protein were treated with vehicle, 
LY294002 (PI3K pathway inhibitor), MSA or sodium selenite for 6 hours. A. Representative 
confocal microscopy images for U2foxRELOC cells. Left row (green) indicates the 
subcellular location of FOXO3a-GFP. Celltracker location (red) identifies the cytoplasm. 
Scale bar, 5 μm. B. Box and whiskers plot for the correlation between the nuclear and 
cytoplasmic green fluorescence intensity. Higher values represent a higher FOXO3a-GFP 
presence in the nucleus compared to the cytoplasm. Bar graph shows the percentage of the 
cells in each condition exhibiting nuclear/cytoplasmic ratios of fluorescence intensity greater 
than 3.5. MSA and LY294002 treatments display statistically significant differences (*) with 
the control condition using a multiple rang test (Kruskal-Wallis test) with 99% confidence. 
C. Viability assay with MSA in U2foxRELOC cells at 72 h. Exponentially growing cells 
were treated with the indicated concentration of MSA for 72 h. The assay was carried out 
using six replicates and repeated three times. Data are represented as mean ± SD.
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Figure 5. MSA induces GFP-FOXO3a nuclear translocation and increases endogenous nuclear 
FOXO3a in A549 cells
A. Representative confocal microscopy images for A549 cells transfected with a FOXO3a-
GFP reporter plasmid and treated with vehicle, 20 μM LY294002 or 5 μM MSA for 6 h. Left 
row (green) indicates the intracellular location of FOXO3a-GFP. Celltracker location (red) 
identifies the cytoplasm. Scale bar, 5 μm. B. Box and whiskers plot for the correlation 
between the nuclear and cytoplasmic green fluorescence intensity. Higher values indicate a 
higher FOXO3a-GFP presence in the nucleus compared to the cytoplasm. Bar graph 
represents the percentage of the cells in each condition displaying nuclear/cytoplasmic ratios 
of fluorescence intensity greater than 1.5. MSA and LY294002 treatments present 
statistically significant differences (*) with the control condition using a multiple rang test 
(Kruskal-Wallis test) with 99% confidence. C. Western blots for the nuclear and cytoplasmic 
fractions of A549 cells. Protein expression levels were quantified using ImageJ software and 
are expressed as mean band intensity normalised to Lamin B (nuclear extract) or ERK 2 
(cytosolic extract) and related to untreated controls. Endogenous nuclear FOXO3a levels 
increase with 6 h MSA and LY294002 treatments whereas phosphorylated FOXO3a 
cytoplasmic levels decrease (*, p < 0.05). D. mRNA levels of FOXO1 were analysed by 
qRT-PCR. Cells were incubated with 5 μM MSA from 1 h up to 24 h. The graph bar 
represents the expression of FOXO1 relative to control, which was assigned a value of 1. 
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FOXO1 expression was significantly (*, p < 0.05) and progressively induced from 2 h to 24 
h.
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Figure 6. MSA-induced G1 arrest and apoptosis are associated with Akt inhibition
Total protein fractions of A549 cells were analysed by Western blot. Protein expression was 
quantified by densitometric analysis using ImageJ software and is represented as mean band 
intensity normalised to β-actin and related to untreated controls. MSA induces the 
dephosphorylation of mTOR and Akt and its downstream target PRAS-40, the 
phosphorylation of JNK, an increase of FOXO3a levels, a reduction of FOXM1 protein 
expression and a G1 arrest represented by p27 accumulation. Differences between treated 
and control groups were considered statistically significant at p < 0.05 (*).
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Figure 7. ROS detoxification by MSA treatment
A decrease in ROS levels was observed in MSA-treated A549 cells. This reduction was only 
statistically significant after 24 and 48 h (*, p< 0.05). Cells treated with sodium selenite for 
24 h presented similar ROS level to MSA-treated cells but significantly enhanced the 
production of ROS in a time-dependent manner after 48 and 72 h incubations.
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Figure 8. Effects of FOXO3a knockdown on MSA activity
U2OS and HEK293 cells were stably transfected with control shRNA (Ctrl) or constructs 
expressing two different FOXO3a-specific shRNA sequences (FOXO3a #1 and FOXO3a 
#2). A. Western blot analysis of total protein fractions of U2OS and HEK293 cells. β-actin 
was used as a protein loading control. Sequence #1 exhibited the highest knockdown 
efficiency. B and C. Viability assays after treatment with 1 μM MSA for 72 h in B. U2OS 
shRNA transfected cells and C. HEK293 shRNA transfected cells. Data are expressed as 
percentage of viability relative to untreated cells. D and E. Cell cycle analysis of 1 μM 
MSA-treated cells for 72 h in D. U2OS shRNA transfected cells and E. HEK293 shRNA 
transfected cells. Cell cycle analysis was conducted after propidium iodide staining. F and 
G. Percentage of early apoptotic cells relative to untreated Ctrl shRNA cells obtained by 
flow cytometry analysis of Annexin V-FITC staining and propidium iodide accumulation 
after exposure of F. U2OS shRNA transfected cells and G. HEK293 shRNA transfected cells 
to 1 μM MSA for 72 h. H and I. Intracellular ROS levels determined by flow cytometry after 
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1 μM MSA incubation for 48 h of H. U2OS shRNA transfected cells and I. HEK293 shRNA 
transfected cells. Results are expressed as percentage of mean fluorescent intensity relative 
to untreated Ctrl shRNA cells. In all cases, values represent mean ± SD and statistically 
significant differences between treated and control cells at p < 0.05 are indicated with an 
asterisk (*).
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Figure 9. Effect of MSA on cell viability
A. Viability assays with MSA in NCI-H460, HCT116 and differentiated 3T3-L1 cells. B. 
Comparison between the 72hIC50 values for the tested cell lines. The MSA concentration that 
caused 50% of inhibition of cell viability at 72 h of treatment for the 3T3-L1 non-tumour 
cell line was three to five times the value for all tumour cell lines analysed.
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Table 1
Synergistic antiproliferative effect of MSA and cisplatin combination treatment
Cells were treated for 72 h at the indicated concentrations of MSA and cisplatin in a constant ratio. A. A549 
cells, ratio 1:10. B. HCT116 cells, ratio 1:5. C. MCF7 cells, ratio 1:4. D. OVCAR3 cells, ratio 1:5. The CI 
results obtained with CompuSyn software revealed a synergy (CI<1) in the antiproliferative effects of MSA 
and cisplatin at each dose combination tested.
A. A549 cells, ratio 1:10.
MSA (μM) Cisplatin (μM) Viability (%) CI Value
0.05 0.5 91.1 ± 1.8 0.570
0.1 1 78.9 ± 1.1 0.447
0.3 3 56.5 ± 2.0 0.631
0.5 5 41.1 ± 3.4 0.707
0.75 7.5 27.9 ± 2.6 0.751
1 10 17.3 ± 0.5 0.729
1.3 13 8.5 ± 0.5 0.663
1.5 15 4.2 ± 0.5 0.578
2 20 1.8 ± 0.5 0.595
B. HCT116 cells, ratio 1:5.
MSA (μM) Cisplatin (μM) Viability (%) CI Value
0.75 3.75 74.5 ± 4.9 0.717
1 5 62.8 ± 3.9 0.667
1.5 7.5 45.1 ± 3.0 0.669
2 10 34.9 ± 3.9 0.725
2.5 12.5 26.0 ± 2.4 0.750
3 15 16.8 ± 2.1 0.716
3.5 17.5 11.0 ± 1.3 0.695
4 20 3.6 ± 0.7 0.517
5 25 2.6 ± 0.6 0.579
C. MCF7 cells, ratio 1:4.
MSA (μM) Cisplatin (μM) Viability (%) CI Value
0.5 2 78.0 ± 1.2 0.275
0.75 3 74.6 ± 2.3 0.363
1 4 74.1 ± 2.1 0.476
1.5 6 70.2 ± 0.5 0.629
2 8 66.6 ± 0.1 0.753
2.5 10 49.5 ± 2.3 0.608
3 12 39.5 ± 3.2 0.575
3.5 14 19.9 ± 2.1 0.392
4 16 13.5 ± 1.4 0.350
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D. OVCAR3 cells, ratio 1:5.
MSA (μM) Cisplatin (μM) Viability (%) CI Value
0.75 3.75 49.8 ± 2.9 0.431
1 5 36.7 ± 2.6 0.446
1.5 7.5 25.5 ± 2.3 0.523
2 10 18.4 ± 1.1 0.573
2.5 12.5 11.6 ± 0.7 0.555
3 15 7.4 ± 0.6 0.530
3.5 17.5 6.9 ± 0.4 0.597
4 20 4.6 ± 0.2 0.557
5 25 2.7 ± 0.6 0.538
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Table 2
Synergistic antiproliferative effect of MSA and carboplatin combination treatment.Cells were treated for 72 h 
at the indicated concentrations of MSA and carboplatin in a constant ratio. A. A549 cells, ratio 1:6. B. 
HCT116 cells, ratio 1:10. C. MCF7 cells, ratio 1:6. D. OVCAR3 cells, ratio 1:6. The CI results obtained with 
CompuSyn software revealed a synergistic (CI<1) antiproliferative effect of MSA and carboplatin at each dose 
combination tested.
A. A549 cells, ratio 1:6.
MSA (μM) Cisplatin (μM) Viability (%) CI Value
0.5 3 81.2 ± 4.1 0.408
0.75 4.5 71.3 ± 5.2 0.642
1 6 61.2 ± 0.4 0.637
1.5 9 48.2 ± 1.4 0.775
2 12 30.7 ± 3.2 0.781
2.5 15 19.3 ± 0.9 0.626
3 18 12.8 ± 2.1 0.792
3.5 21 10.5 ± 1.3 0.816
4 24 8.1 ± 0.5 0.887
B. HCT116 cells, ratio 1:10.
MSA (μM) Cisplatin (μM) Viability (%) CI Value
0.25 2.5 89 ± 1.3 0.306
0.5 5 77 ± 1.9 0.398
1 10 72 ± 0.2 0.661
1.5 15 55 ± 0.6 0.731
2 20 38 ± 3.4 0.711
2.5 25 22 ± 2.0 0.674
3 30 14 ± 0.6 0.692
3.5 35 12 ± 1.5 0.752
4 40 4 ± 2.8 0.608
5 50 2 ± 0.6 0.567
C. MCF7 cells, ratio 1:6.
MSA (μM) Cisplatin (μM) Viability (%) CI Value
0.5 3 84.9 ± 5.4 0.295
0.75 4.5 70.3 ± 3.9 0.299
1 6 63.5 ± 5.0 0.347
1.5 9 55.2 ± 2.0 0.445
2 12 46.7 ± 4.3 0.510
2.5 15 36.1 ± 5.0 0.523
3 18 15.8 ± 4.2 0.381
3.5 21 13.4 ± 1.3 0.408
4 24 11.2 ± 0.7 0.424
5 30 8.7 ± 0.7 0.469
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D. OVCAR3 cells, ratio 1:6.
MSA (μM) Cisplatin (μM) Viability (%) CI Value
0.75 4.5 85.1 ± 1.8 0.668
1 6 77.5 ± 5.1 0.697
1.5 9 66.9 ± 0.5 0.908
2 12 44.4 ± 0.0 0.862
2.5 15 37.1 ± 1.0 0.966
3 18 24.7 ± 0.6 0.937
3.5 21 14.9 ± 0.1 0.874
4 24 6.5 ± 2.0 0.719
5 30 3.2 ± 0.6 0.686
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